|
89
|
290
|
5tq3A |
Design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin |
|
92
|
282
|
5tt7A |
Discovery of tak-659, an orally available investigational inhibitor of spleen tyrosine kinase (syk) |
|
88
|
292
|
5tq7A |
Design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin |
|
75
|
272
|
5to8A |
Selectivity switch between fak and pyk2: macrocyclization of fak inhibitors improves pyk2 potency |
|
85
|
287
|
5ttsA |
Jak3 with covalent inhibitor 4 |
|
101
|
291
|
5tq8A |
Design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin |
|
83
|
286
|
5tozA |
Jak3 with covalent inhibitor pf-06651600 |
|
66
|
278
|
5tehA |
C-src v281c kinase domain in complex with rao-iv-156 |
|
96
|
291
|
5tq5A |
Design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin |
|
106
|
334
|
5twlA |
Structure of maternal embryonic leucine zipper kinase |
|
86
|
285
|
5ttuA |
Jak3 with covalent inhibitor 7 |
|
79
|
287
|
5ttvA |
Jak3 with covalent inhibitor 6 |
|
90
|
290
|
5tq6A |
Design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin |
|
88
|
277
|
5tiuA |
Crystal structure of syk kinase domain with inhibitor |
|
75
|
334
|
5twyA |
Structure of maternal embryonic leucine zipper kinase |
|
110
|
334
|
5tvtA |
Structure of maternal embryonic leucine zipper kinase |
|
86
|
278
|
5tr6A |
Discovery of tak-659, an orally available investigational inhibitor of spleen tyrosine kinase (syk) |
|
82
|
286
|
5tkdA |
Crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with 6-[(3,5-dimethylphe nyl)amino]-8- (methylamino)imidazo[1,2-b]pyridazine-3-carbo xamide |
|
81
|
275
|
5t68A |
Crystal structure of syk catalytic domain in complex with a furo[3,2-d]pyrimidine |
|
75
|
276
|
5sysA |
C-src v281c bound to n-[3-({6-[(1e)-2-cyano-3-(methylamino)-3-oxoprop-1-en-1-yl]-7-(2-methoxyethyl)-7h-pyrrolo[2,3-d]pyrimidin-5-yl}ethynyl)-4-methylphenyl]-3-(trifluoromethyl)benzamide inhibitor |
|
85
|
265
|
5t18A |
Crystal structure of bruton agammabulinemia tyrosine kinase complexed with bms-986142 aka (2s)-6-fluoro-5-[3-(8-fluoro-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)-2-methylphenyl]-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1h-carbazole-8-carboxamide |
|
73
|
277
|
5t0pA |
C-src kinase domain in complex with rao-iv-151 |
|
89
|
266
|
5p9jA |
Btk1 cocrystallized with ibrutinib |
|
90
|
265
|
5p9gA |
Structure of btk with rn486 |
|
95
|
266
|
5p9fA |
Btk in complex with gdc-0834 |
|
95
|
271
|
5p9mA |
Btk1 binds covalently to hy-15771 ono-4059 |
|
92
|
271
|
5p9kA |
Crystal structure of btk with cnx 774 |
|
82
|
266
|
5p9lA |
Btk1 in complex with cc 292 |
|
73
|
264
|
5p9hA |
Btk1 cocrystallized with rn983 |
|
89
|
271
|
5p9iA |
Btk1 soaked with ibrutinib-rev |
|
11
|
57
|
5oavA |
High resolution crystal structure of the c-src-sh3 domain mutant e93v in complex with the high affinity synthetic peptide app12: monoclinic crystal |
|
11
|
57
|
5ob0A |
Crystal structure of the c-src-sh3 domain q128e mutant in complex with the high affinity peptide app12 |
|
11
|
56
|
5ob2A |
Crystal structure of the c-src-sh3 domain e97t mutant in complex with the high affinity peptide app12 |
|
13
|
57
|
5ob1A |
Crystal structure of the c-src-sh3 domain q128r mutant in complex with the high affinity peptide app12 |
|
10
|
59
|
5oazA |
Crystal structure of the abl-sh3 domain at ph 7.5 |
|
11
|
54
|
5nuhC |
Crystal structure of sivmac239 nef bound to an engineered hck sh3 domain |
|
11
|
57
|
5np3A |
Abl2 sh3 |
|
8
|
57
|
5np2A |
Abl1 sh3 ptyr89/134 |
|
87
|
295
|
5ng0A |
Structure of rip2k(l294f) with bound amppcp |
|
8
|
61
|
5np5A |
Abl2 sh3 ptyr116/161 |
|
0
|
8
|
5nnfB |
Crystal structure of the first bromodomain of human brd4 in complex with an acetylated baz1b peptide (k221ac) |
|
89
|
291
|
5c03A |
Crystal structure of kinase |
|
102
|
289
|
4ytiA |
Discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune disease |
|
81
|
289
|
5c01A |
Crystal structure of kinase |
|
95
|
270
|
5lmaA |
Human spleen tyrosine kinase kinase domain in complex with azanaphthyridine inhibitor |
|
93
|
290
|
4zimA |
Crystal structure of janus kinase 2 in complex with a 9h-carbazole-1-carboxamide inhibitor |
|
90
|
274
|
5c27A |
Crystal structure of syk in complex with compound 2 |
|
84
|
275
|
5bmmA |
Src in complex with dna-templated macrocyclic inhibitor mc25b |
|
85
|
263
|
5j87A |
Discovery of n-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (chmfl-btk-01) as a highly selective irreversible btk kinase inhibitor |
|
84
|
262
|
5jrsA |
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with 4-[2-fluoro-3-(4-oxo -3,4-dihydroquinazolin-3-yl)phenyl]-7-(2-hydroxypropan-2-y l)-9h-carbazole-1-carboxamide |
